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Slllnl'l'lary 
Expression of Thy-1 on hematopoietic cells from human fetal liver (FL), cord blood (CB), and 
bone marrow (BM) was studied with a novel anti-Thy-1 antibody, 5E10.  Specificity of 5E10 
for human Thy-1 was demonstrated by immunoprecipitation of a 25-35-kD molecule, and the 
sequence of a cDNA that was cloned by immunoselection of COS cells transfected with a cDNA 
library derived from  a  5E10 §  cell line.  Two-  and  three-color immunofluorescence staining 
experiments revealed  that the Thy-1 expression is restricted to, on average,  1-4%  of FL, CB, 
and BM cells, and binding to these cell types is essentially restricted to a very small subset of 
lymphoid cells and ~25%  of CD34 + cells. Thy-1 +  CD34 + cells were further characterized as 
CD38~~  +/CD45RA-/CD711~  1~ and rhodamine 123 a~n. When CD34 + cells were 
sorted on the basis of Thy-1 expression, the majority of clonogenic cells were recovered in the 
CD34+Thy-1-  fraction, whereas the majority of cells capable of producing myeloid colonies 
after 5-8 wk of long-term culture (long-term culture initiating cells) were recovered in the Thy- 
1+CD34 + fraction. In addition to CD34 + cells, Thy-1 was found to be expressed on a variable, 
very small number (<1%) of CD34-  mononuclear cdls in BM, CB, and peripheral blood that 
were further characterized as CD3 +CD4 + lymphocytes. The restricted expression of Thy-1 on 
primitive hematopoietic cells is in agreement with a previous report (Baum et al.,  1992. Proc. 
Natl.  Acad.  Sci.  USA.  89:2804)  in which Thy-1 expression was used to enrich for primitive 
hematopoietic cells from fetal tissue.  Compared with those previous studies, we found Thy-1 
expression on a larger proportion of CD34 + cells (25%  in our study vs. 5%  in Baum et al.) 
and furthermore performed studies on Thy-1 expression on CD34 + cells from CB, FL, and BM 
in relation to markers that are known to be differentially expressed on hematopoietic cells. Taken 
together our results indicate that Thy-l-specific antibody 5E10 is an attractive tool for further 
studies on the biology and purification of human stem cells. 
T 
he hematopoietic system consists of a highly heteroge- 
neous mixture of cells at various stages  of differentia- 
tion. The majority of these cells have limited life spans and 
limited or no proliferative potential. Cell number is main- 
tained through the proliferation of a small number of pluripo- 
tent stem cells and their immediate progeny, the cells of the 
progenitor cell compartment (1). Both stem cells and their 
progeny express CD34, a highly glycosylated cell surface pro- 
tein present on 1-4%  of low density bone marrow (BM) 1 
1 Abbreviations used in tkis~per: BM, bone marrow; CB, cord blood; CFC, 
colony-forming cells; FL, fetal liver;  HFN, Hank's Hepes buffered salt 
solution containing 2% FCS and 0.1% sodium azide; HPP, high proliferative 
potential; LTC-IC, long-term culture initiating cells; NHS, normal human 
serum; NSS, normal sheep serum; PB, peripheral  blood; PI, propidium 
iodide;  PC), peroxidase;  SA-HRPO, Streptavidin-conjugated horseradish 
peroxidase;  SA-RPE, Streptavidin-R phycoerythrin; TNP, trinitophenol. 
mononuclear cells (2).  mAbs against CD34 have been the 
primary tool used for the purification of human stem cells, 
either in immunoadsorption (panning) procedures, immunoab- 
sorbance columns, magnetic separations, or in flow cytom- 
etry (reviewed in reference 3). CD34 + cells are highly het- 
erogeneous both functionally and in the markers they express; 
therefore, additional mAbs have been used to subdivide the 
CD34  compartment. Most current techniques for further 
purification of the most primitive CD34 + cells have relied 
on  negative selection.  Antibodies  against  various  lineage 
markers (4), transferrin receptor (CD71) (5, 6), the high mo- 
lecular  weight  isoform  of the  human  leukocyte antigen 
(CD45RA) (6, 7), CD33 (8, 9), CD38 (10), and HLA-DR 
(5, 11), have been used by different groups for this purpose. 
We have investigated the use of novel mAbs raised against 
the human erythroid leukemia hematopoietic cell line HEL 
(12) for the further subdivision of cells that express CD34. 
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tion of BM cells (1-4%), including '~25% of CD34 + cells 
and a small subset of lymphoid cells.  Further experiments 
showed that the subpopulation of CD34 + cells recognized 
by 5E10 is highly enriched for phenotypically and function- 
ally very primitive hematopoietic precursor cells and that the 
molecule recognized by 5E10 is Thy-1. In view of this finding 
and a recent report indicating that Thy-I is expressed on a 
candidate human hematopoietic stem cell population from 
fetal BM (4), we wished to correlate expression of Thy-1 on 
CD34 + cells from adult BM in relation to markers that are 
known  to be preferentially expressed on functionally dis- 
tinct hematopoietic subpopulations of such cells as well as 
CD34 + cells derived from fetal liver (FL) and umbilical cord 
blood (CB). 
Materials and Methods 
Cells.  Heparinized BM samples were obtained from informed 
and consenting individuals donating for allogeneic transplantation. 
CB samples were obtained from the umbilical cord at the time of 
birth from full-term pregnancies (kindly provided  by Dr. J. O'Toole 
and his colleagues at the Royal Columbian Hospital, Coquitlam, 
BC). Peripheral blood (PB) samples were donated by healthy con- 
senting volunteers. FL cells were obtained from elective,  therapeutic 
abortions, in the 12-20th week of gestation. Low density mono- 
nuclear cells (<1.077 g/cm  3) were isolated by density separation 
using Ficoll-Paque  (Pharmacia LKB, Uppsala, Sweden). Interphase 
cells were removed and washed twice in Hank's  Hepes buffered 
salt solution containing 2% FCS and 0.1% sodium azide (HFN) 
before being resuspended at 107 cells/ml in HFN  +  5% normal 
human serum (NHS) to block Fc receptors (FcK). For some ex- 
periments, RBC were lysed  by mixing samples with a 10-fold  excess 
of ammonium chloride lysing solution.  Samples were incubated 
for 15 rain on ice, pelleted, and washed twice in HFN. 
HEL, K562, KGla, DHL4, CCKF-CEM,  MOLT4, HUT78, 
and Sp2/OAg14 (a murine myeloma line) cell line cells were all 
obtained  from American  Type Culture  Collection  (Ikockville, 
MD) and grown in DME supplemented with 10% FCS and 5  x 
10 -s M 2-ME (DME 10). 
Antibodies.  IgG1  mAbs  specific for  CD34  (8G12), CD71 
(OKTg), CD45RA (8D2), CD38 (THB7), and 5E10  were purified 
from tissue culture supernatants using protein G (Pharmacia  LKB). 
8G12 labeled with cyanine 5 was previously described (6), and used 
at 10/~g/ml.  OKT9, 8D2,  and THB7 were labeled with FITC 
(F-7250; Sigma Chemical Co., St. Louis, MO), and were used at 
1, 2, and 2/~g/ml, respectively.  5E10  was labeled  either with fluores- 
cein (5  and 6-carboxyfluorescein succinimydyl ester; Molecular 
Probes, Eugene, OIL) or biotin (biotin xx succinimydyl  ester; Mo- 
lecular Probes) and used at 8 and 4/zg/ml, respectively. Ascitic 
fluid containing 17Fll, an anti-c-kit Ab (IgM), was obtained from 
AMAC Monodonal Antibodies (Westbrook, ME) and was used 
at a dilution of 1:1,000. Biotinylated goat anti-mouse IgG (biotin- 
anti-mlg, 115-065-062;  Jackson, Westgrove,  PA) was diluted 200x 
in HFN containing 5% normal sheep serum (NSS) and 5% NHS. 
Generation Of 5EIO.  Female  BALB/c mice were injected with 
107 HEL cells suspended in CFA. Mice were boosted with  107 
HEL cells 4 wk later, 4 d before the fusion was performed. Spleens 
were disaggregated to form a single-cell  suspension, and cells fused 
at a ratio of five spleen cells to one Sp2/0 Ag14 cell. Hybridomas 
were plated in DME 10 + hypoxanthine, aminopterin, and thymi- 
dine (HAT) + 50 U/m111.-6 (tk & D Systems, Minneapolis, MN). 
After 7 d, media were removed and fresh DME 10  +  hypoxan- 
thine, thymidine +  10 U/ml II,6 was added. Hybridoma superna- 
rants were screened on day 13 or 14 by ELISA as previously de- 
scribed (13). Briefly, 60-well Terasaki plates were coated with low 
density PBL or HEL cells. Plates were incubated with undiluted 
hybridoma supematants, followed  by a peroxidase-conjugated  sheep 
anti-mouse  secondary antibody (Dimension Laboratories, Missis- 
sauga, Ontario), and finally with the substrate solution containing 
O-phenylenediamine  dihydrochloride  (OPD; Sigma Chemical Co.). 
Hybridomas producing Abs that reacted with HEL cells, but not 
PBL, were then tested by flow cytometry on low density BM 
mononudear cells for reactivity with CD34*  cells. Hybridomas 
were  cloned by plating  cells in  semisolid methylcellulose and 
plucking colonies. Clones were selected by ELISA on HEL cells. 
Flow Cytometry.  All staining procedures were performed at a 
cell concentration  of 107/ml. Indirect  staining  techniques were 
used for most experiments. Cells were incubated with 5E10 or con- 
trol IgG1 antibody specific  for either trinitrophenol (TNP) or per- 
oxidase (PO) at 4~  for 30 rain,  followed by two washes with 
HFN. Samples were resuspended in biotin-anti-mlg  (1:200 dilu- 
tion in HFN  +  5% NSS +  5% NHS), incubated for 30 min at 
4~  washed twice in HFN, and resuspended in a half volume of 
an irrelevant mAb (100/~g/ml  of mlgG1  anti-TNP in HFN) to 
block any residual biotin anti-mlg. Samples were incubated for 10 
rain  at  4~  Directly  conjugated  mAbs  and  Streptavidin-lk 
phycoerythrin (SA-ILPE; Molecular Probes) were then added and 
cells incubated for an additional 30 rain at 4~  washed twice in 
HFN, and resuspended in HFN + propidium iodide (PI; p-5264; 
Sigma Chemical Co.) at 1/zg/ml. Alternatively, cells were labeled 
with either directly labeled (5E10-FITC) or biotinylated 5E10 fol- 
lowed by SA-RPE or avidin-FITC (3/~g/ml; Becton Dickinson & 
Co., San Jose, CA). c-kit-stained samples were incubated with 17Fll 
(1:1,000 ascites) in the first step, followed by biotin anti-mlg, and 
SA-RPE. Staining was then amplified by two successive  rounds of 
incubation with a biotinylated anti-RPE mAb (1/~g/ml) followed 
by 2/~g/ml SA-RPE (14). Parallel samples were stained with an 
irrelevant IgM antibody. 
Rhodamine  123  (R.h123)-stained samples were labeled with 
R.h123 before Ab staining. Cells were resuspended  in HF + P,.h123 
(Molecular Probes) at 0.1/~g/ml, incubated for 20 rain at 37~ 
and washed twice in HF. Samples were then split and incubated 
for 20 min  at  either  4  or 37~  washed twice  in  HFN,  and 
resuspended in HFN +  5% NHS for Ab staining. Analysis  and/or 
sorting of cells was performed on a FACStar Plus* (Becton Dick- 
inson & Co.) equipped with a 5-W Argon and a 30-row helium 
neon laser (Spectra-Physics, Mountain  View, CA). 
Staining of CD34-  5E102+ Cells with Lineage Markers.  Anti- 
Leu-4 (anti-CD3), anti-Leu-2a  (anti-CD8), anti-Leu-3a  (anti-CD4), 
anti-Leu-19-PE (anti-CD56), and anti-Leu-12-FITC  (anti-CD9) v~re 
obtained from Becton Dickinson & Co.). Ml10 (anti-CD13), M138 
(anti-CD14), and Ml12 (anti-CD9) ascitic fluids were part of the 
myeloid panel from the Fourth International  Leukocyte Typing 
Workshop and were used at a 1:1,000  dilution. Cells were incubated 
with unlabeled primary Ab at 4~  for 30 min, washed twice in 
HFN, and resuspended  in a 1:100 dilution of FITC-conjugated sheep 
anti-mouse (SAM-FITC; Jackson Immunoresearch Laboratories, 
West Grove, PA) in HFN +  5% NHS +  5% NSS. Samples were 
incubated for 30 rain at 4~  washed twice in HFN, resuspended 
in irrelevant mouse IgG, and incubated for 10 min at 4~  to block 
residual SAM-FITC. Samples were then labeled with biotinylated 
Abs (5E10-b or mlgG-b), followed by SA-RPE or A-FITC, 8G12- 
CyS, PI, and directly conjugated mAbs. 
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and progenitor assays  were performed as previously described (11), 
except for the addition to methylcellulose  cultures of 20 ng/ml of 
the GM-CSF/IL-3 fusion protein (15) and 50 ng/ml human mast 
cell growth factor (MGF; c-kit ligand) (16) which were both kindly 
provided by Dr. D. E. Williams (Immunex, Seattle, WA). Sorted 
cells were plated in long-term cultures and methylcellulose pro- 
genitor assays. Methylcellulose colonies were counted on day 14 
to determine the number of colony-forming cells (CFC) in the 
original sample, and at day 28 to determine the number of high 
proliferative potential CFC (HPP-CFC) (17). HPP-CFC are late- 
appearing, large (>1 mm in size) densely  packed colonies  composed 
of >50,000 cells. Colonies are primarily composed of granulocytes 
although some monocytes  may be present. Long-term cultures were 
harvested at 5 and 8 wk, and colony assays  performed to determine 
the number of long-term culture-initiating cells (LTC-IC) present 
in the original samples (11). The number of LTC-IC present ini- 
tially is linearly related to the number of clonogenic cells present 
after 5-8 wk, with LTC-IC producing an average of four clono- 
genic cells in standard methylcellulose cultures (18). 
5E10 Immunoprecipitation.  DHL4 (5E10  +) and CCKF-CEM 
(5E10-) cells were washed twice in HBSS, and 107 cells were lysed 
at a final concentration of 2  x  107 cells/ml in 0.5% NP-40, 50 
mM Hepes, 100 mM NaF, 100 mM NaPi, 2 mM Na3VO~, 2 mM 
EDTA + 2 gg/ml leupeptin, 5 mM PMSF (Sigma Chemical Co.), 
and 100 Kallikrein  inhibitor U/ml aprotinin, pH 7.5. Lysed  samples 
were then microfuged for 10 min at 10,000 rpm to remove cell 
debris, and supernatants were transferred to new tubes. Cell lysates 
were precleared by two successive  rounds of incubation with anti- 
TNP-bound protein A-Sepharose  beads (Sigma  Chemical  Co.). Anti- 
TNP (an irrelevant IgG1 control mAb) was added at 5/~g/ml to 
protein A-Sepharose beads and incubated for 30 min at 4~  150 
/zl of this Ab/bead mixture was added to cell lysates, samples were 
mixed at 4~  on a Nutator for 60 min, and beads were pelleted 
by microfuging at maximum speed for I rain. Supernatants were 
transferred to new tubes, and the preclearing was repeated. For 
immunoprecipitation, unlabeled 5E10 or an isotype-matched con- 
trol Ab (anti-TNP) was added at a final concentration of 5 gg/ml 
to the cleared lysates, and samples were mixed on a Nutator for 
30 rain at 4~  20/zl of  protein A-Sepharose  beads was then added 
to each tube, and samples were mixed on a Nutator for 60 min 
at 4~  The beads were then pelleted and washed three times in 
low salt buffer (0.2% NP-40, 2 mM EDTA, 10 mM Tris, pH 7.5, 
150 mM NaC1), twice in high salt buffer (0.2% NP-40, 2 mM 
EDTA, 10 mM Tris, pH 7.5, 500 mM NaC1), and once in 10 mM 
Tris. 4x SDS sample buffer (30% glycerol,  25% 2-ME, 9.2% SDS, 
0.8% bromphenol blue), and dHaO were added to a final  volume 
of 160 #1 and samples were boiled for 2 min. Proteins were sepa- 
rated on a 20-cm 15% SDS-PAGE gel and were electroblotted to 
Immobilon P (Millipore, Mississauga, Ontario). The Immobilon 
membrane was blocked by incubating for 2 h at room temperature 
in blocking solution. Bands were then electroblotted to an Im- 
mobilon membrane using a transblot apparatus (Bio-Rad Labora- 
tories, Richmond, CA). The membrane was incubated for 2 h at 
room temperature in blocking solution (2% BSA, 0.05% NAN3, 
0.05% Tween in PBS), followed  by three 5-min rinses in wash so- 
lution (0.1% BSA, 0.05% Tween  in PBS). The membrane was then 
transferred to a solution containing 0.5/~g/ml 5E10 biotin in wash 
solution, incubated for 30 rain at room temperature, and rinsed 
three times in wash solution. The membrane was then incubated 
for 60 min in a solution of  Streptavidin-conjugated  horseradish  per- 
oxidase (SA-HRPO; Bio-Can, Mississauga, Ontario) (1:20,000 in 
wash solution), rinsed four times in wash solution, and once in 
PBS. The blot was developed using enhanced chemiluminescence 
(ECL) substrate solution (Amersham, Oakville, Ontario) according 
to manufacturer's instructions and exposed for 2 min to Kodak 
Xomat AR film. 
cDNA Immunoselection and Sequencing.  cDNA was synthesized 
from HEL cell mRNA as described (19) and cloned into pAX142, 
which is a variant of the pAX114 expression vector (20). Plasmid 
DNA of the cDNA library was transfected into COS-1 cells (21) 
by electroporation (20). 3 d later, the transfected  cells were treated 
with 5E10 mAb and then panned on dishes coated with goat 
anti-mouse IgG. Plasmids were then recovered from the adherent 
cells by alkaline  lysis, recloned  by transformation ofEsckerichia coli, 
and retransfected into COS cells. These procedures have been de- 
scribed in detail previously (20). 
The sequence of the cDNA was determined by the chain termi- 
nation method, using Sequenase enzyme and procedures supplied 
by United States Biochem. Corp. (Cleveland,  OH). Sequence  anal- 
ysis and data base searching were performed with the GCG soft- 
ware package (22). 
Results 
Generation of mAb  5EI0.  Spleen  cells  from  mice  im- 
munized with HEL cells were fused with Sp2/0 myeloma 
cells and plated in selective media. Approximately 1,000 hy- 
bridoma supernatants were screened for reactivity with HEL 
cells and PBL by ELISA. 12 supernatants appeared HEL specific 
by ELISA and reactivity was confirmed by flow cytometry. 
Low density BM mononuclear cells were double stained with 
supernatants of cloned hybridomas and 8G12-FITC  (anti- 
CD34) to examine reactivity with CD34 + cells. Gates were 
set as shown in Fig.  1 to exclude dead (PI +) and high side 
scatter (SSC) ceils, mAb 5E10 labeled a minority of BM cells, 
including a subpopulation of CD34 + cells, and was selected 
for further study. It was difficult to discriminate between 5EIO- 
and control-stained samples without gating on CD34 + calls 
(Fig. 2, A and B). Approximately 25% of the cells that were 
CD34  bright were 5E10  + (Fig.  2,  C  and D).  The deter- 
minant recognized by 5E10 is apparently expressed  at very 
low levels as normal cells stained with directly conjugated 
5E10 reagents were weakly stained (Fig.  2, E  and G) even 
though certain cell lines were very brightly labeled by iden- 
tical reagents. 
5E10 Immunoprecipitates a 25-35-kD Protein.  Several  human 
hematopoietic cell lines were examined for 5E10 staining. 
CCRF-CEM, MOLT4, and HUT78 are T cell lines, DHL4 
is a B cell lymphoma line,  and K562, HEL, and KGla are 
all leukemic lines with various characteristics  of early hema- 
topoietic blast cells. HEL, DHL4, and HUT78 were brightly 
stained by 5E10, MOLT4 only wealdy, and K562 and CCRF- 
CEM  not at  all.  Only a  few percent  of KGla cells were 
5E10 + , but staining was weak (data not shown). From these 
results, it was decided to use DHL4 cells (brightest staining) 
and CCRF-CEM (lowest background staining) for immu- 
noprecipitation with 5E10. DHL4 (Fig. 3, lanes 1 and 2) and 
CCRF-CEM (Fig. 3, lanes 3 and 4) cells were lysed and im- 
munoprecipitated with either 5E10 (Fig.  3, lanes  1 and 3) 
or an isotype-matched irrelevant  control antibody (Fig.  3, 
lanes 2 and 4).  Immune complexes  were then run on 15% 
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Figure  2.  Direct vs. indirect staining of cells with 5El0. Low density 
BM mononuclear  cells were labeled with 5E10 or isotype-matched control 
antibody (anti-TNP or anti-PO) together with antibodies against CD34. 
5E10 stains a small population of CD34- cells (.4, box) and 20-30% of 
CD34 + cells. Indirect staining results in the brightest  staining but also 
the highest background.  Note that 5El0 appears to react preferentially 
with CD34 bright cells. 
Figure  1.  Gates used for analysis of antibody 
reactivity with BM cells. BM cells were gated to 
exclude dead cells (A), and include cells with low 
side scatter (SSC)  and low to medium forward light 
scatter (B, FSC), and low side scatter and high 
CD34 expression (C'). The same gates were used 
for CB and FL samples. 
exposed to film. Several weak bands were seen in all lanes, 
but a single broad band at 25-35 kD was specific  for the 5E10- 
immunoprecipitated DHL4 lysates (Fig.  3, lane  1). 
Expression Cloning of  a cDNA Encoding the 5E10 Antigen.  A 
cDNA  encoding the  5El0  antigen  was  isolated  by  im- 
munoselection of a cDNA library expressed in transfected 
COS cells, cDNA was synthesized from HEL cell mRNA 
and ligated into the pAX142 expression vector. Pooled plasmid 
DNA of the cDNA library was transfected into COS-1 cells, 
which were selected for the acquisition of antigen expression 
by panning with the 5EI0 mAb. Plasmids were then isolated 
from the adherent cells, amplified  by transformation into 
E. coli, and retransfected into COS cells. After two such rounds 
of transfection and panning, individual plasmid clones recov- 
ered from the selected cells were tested by FACS  |  for their 
ability to transfer 5E10 reactivity to COS cells. A single clone 
with a 2,000-bp cDNA insert (pSL307c18) produced strong 
and specific reactivity with the 5El0 mAb. Sequence was ob- 
tained from both ends of the pSL307cl8 cDNA and is shown 
for the 5' end in Fig. 4. A search of the GenBank database 
revealed a complete identity with the Thy-1 cDNA (23). Re- 
striction maps of the pSL307cl8 and Thy-1 cDNAs were 
matched throughout their overlapping regions, indicating that 
they were identical except for the extended length of the 5' 
and 3'  noncoding regions of the pSL307cl8 cDNA. 
Functional Analysis  of CD34 + Cells from BM Differing in 
Thy-1 Expression.  Low density BM cells were labeled with 
5E10 and  8G12  (anti-CD34),  sorted into Thy-l-CD34 § 
and Thy-l+CD34 + populations, and plated in long-term 
Figure 3.  5El0  immunoprecipi- 
tates a broad band '~25 kD.  DHL4 
(5E10  +) and CCRF-CEM (5E10-) 
cells were immunoprecipitated  with 
either 5E10  or anti-TNP (an irrelevant 
isotype-matched  control  antibody) 
and Western blotted with 5E10. Lane 
1, DHL4 cells immunopredpitated 
with 5E10; lane 2, DHL4 cells im- 
munopredlx'tated with anti-TNP; lane 
3, CCKF-CEM cells immunoprecip- 
itated with 5E10; lane 4, CCRF-CEM 
cells immunoprecipitated  with anti- 
TNP. The very strong band '~25 kD 
was specific  for DHL4 cells, and was 
not precipitated by the control  an- 
tibody. 
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M 
55  G~CCTGGCCA~AGCATCGCTC~C~CT~CAGTCTTGCA~TC~CCGA~ 
NLAISIALLLTVLQVSRG 
109  GCAG~ACCAGCCT~C~CC~CCTAGTGGACCAGAGCC~CGTCTGGA 
QKVTSLTACLVDQSLRLD 
163  C~CCGCCA~AG~TACCAGCAGT~ACCCATCCAGTACGAG~CA~GCACC 
CRHENTSSSPIQYEFSA 
Figure 4.  Sequence  of the 5' end of the cDNA encoding  5E10  antigen. 
The first 216 bases of the pSL307c18  cDNA are shown, reading  from the 
5' end of the cDNA. The arrow marks the beginning of identity with 
the published  human Thy-1  sequence  (25) (GenBank  accession  no. Ml1749), 
which starts at this position. The translation  beginning at the first initia- 
tion codon is shown below the sequence. 
cuhures and progenitor assays. Sort windows were set to give 
a clear separation of Thy-1 +  and Thy-1-  cells;  therefore, 
some 5E10 weakly stained cells were excluded, resulting in 
poor recoveries for some experiments (Tables  1 and 2).  In 
three of four experiments, myeloid and erythroid CFC were 
depleted in the Thy-1 § fraction while the majority of these 
CFCs were recovered in the Thy-1- fraction (Table 1). HPP- 
CFC,  a more primitive progenitor cell that can be assayed 
in semisolid medium (5), was highly enriched in the Thy-1 + 
fraction (30-160-fold; Table 1) and were either absent from 
or only moderately enriched in the Thy-1- fraction (Table 
1). Similarly, week 5 and 8 LTC-IC (18) were highly enriched 
(48-644- and 72-644-fold, respectively) in the Thy-1 + frac- 
tion (Table 2). These results indicate that Thy-1 expression 
is highest on week 8 LTC-IC, followed by week 5 LTC-IC 
and  HPP-CFC,  and  is  absent  from  the  majority  of ma- 
ture CFC. 
Phenotypic  Analysis  of  Thy-I+CD34 +  Subpopulations  in 
BM,  CB~ andFL.  Thy-l+CD34 + cells were further charac- 
terized by muhiparameter flow cytometry. CB and FL samples 
were included to examine whether Thy-1 expression is al- 
tered during ontogeny. Low density mononuclear cells from 
BM, CB, and FL were labeled in the same experiments with 
5E10, 8G12 (anti-CD34), and either Kh 123 or mAbs specific 
for c-kit,  CD38,  CD71,  or CD45RA.  Dead cells were ex- 
cluded by gating out PI § cells. Additional gates were set to 
exclude cells with high SSC and to restrict analysis to cells 
with medium to high forward scatter (FSC), and high CD34 
expression (Fig.  1).  Profiles for BM,  CB,  and FL CD34 + 
cells are shown in Figs. 5 and 6 and are summarized in Table 
3. Again, without further gating it was difficult to discriminate 
5E10 staining from background staining (compare Fig. 5, A, 
E,  and I  with B, F,  and j).  Up  to 50%  of CD34 + cells 
from FL were Thy-1 + (Fig. 5 D), and this population was 
smaller but dearly present in CD34 + cells from CB and BM 
(Fig.  5, H  and L).  Note that CD45RA expression is low 
on FL cells, high on some CB and BM cells, and that Thy-1 
expression appears restricted to CD34 + CD45RA-  cells in 
adult BM but includes some CD34 +  CD45RA § cells from 
CB (Fig.  5,  D, H, and L). 
c-kit expression was restricted to a few percent of BM, CB, 
Table  1.  Recovery and Enrichment of Colony-forming  Cells over CD34 + Cells Separated on the Basis of Thy-1  Expression 
BFU-E  CFU-GM  HPP-CFC 
Fraction  Percent  Percent  Percent  Percent 
Exp.  sorted  sorted  Frequency  Enrichment  recovery  Frequency Enrichment  recovery  Frequency  Enrichment  recovery 
pert0 s  per l O  s  per2  x  106 
1  Unsorted  100  575  1  100  455  1  100  366  1  100 
Thy-1-CD34  §  2.1  10,750  19  39  13,750  30  63  2,500  6.8  14 
Thy-1+CD34 *  0.56  5,750  10  5.6  17,625  38  21  27,500  75  42 
2  Unsorted  100  830  1  100  580  1  100  2,000  1  100 
Thy-1-CD34 +  2.6  19,900  24  62  5,500  9.5  25  0  0  0 
Thy-1§  +  0.39  500  0.6  0.2  7,400  13  5  60,000  30  12 
3  Unsorted  100  258  1  100  205  1  100  360  1  100 
Thy-1-CD34 §  1.5  9,750  38  53  8,750  43  64  0  0  0 
Thy-1+CD34 §  0.48  9,500  37  18  24,000  117  56  57,500  160  76 
4  Unsorted  100  153  1  100  186  1  100  720  1  100 
Thy-l-CD34 §  1.4  4,600  30  42  8,500  46  64  10,000  13.8  19 
Thy-1§  +  0.15  4,500  29  4.4  7,750  42  6.2  60,000  83  12.5 
BM cells were sorted  on the basis of Thy-1 labeling and CD34 expression, and placed in methylcellulose  cultures. Colony-forming  cells (CFU, BFU) 
were scored on day 14, and HPP-CFC on day 28. Enrichments were calculated  by dividing the frequency  of CFU in sorted fractions  by the frequency 
for unsorted PI- cells. Recoveries  were calculated by multiplying the enrichment by the percent sorted. 
1335  Craig et al. Table  2.  Recovery  and Enrichment of LTC-IC over CD34 + Cells Separated on the Basis of Thy-1 Expression 
Week 5 LTC-IC  Week 8 LTC-IC 
Fraction  Percent  Percent  Percent 
Exp.  sorted  sorted  Frequency  Enrichment  recovery  Frequency  Enrichment  recovery 
per2  x  I06  per2  x  106 
1  Unsorted  100  775  1  100  214  1  100 
Thy-l-CD34 §  2.1  5,250  6.7  0.14  375  1.8  3.8 
Thy-1 +  CD34 §  0.56  159,000  204  114  44,800  209  117 
2  Unsorted  100  1,660  1  100  638  1  100 
Thy-l-CD34 +  2.6  9,150  5.5  14  2,550  4  10 
Thy-1§  +  0.39  80,500  48  19  45,900  72  28 
3  Unsorted  100 
Thy-1-CD34 §  1.5  ND  ND  ND  ND  ND  ND 
Thy-1 +  CD34 +  0.48 
4  Unsorted  100  174  1  100  68  1  100 
Thy-  1 - CD34 +  1.4  3,000  17  24  900  13  18 
Thy-1+CD34 §  0.015  112,000  644  97  43,800  644  97 
BM cells were sorted on the basis of Thy-1 labeling and CD34 expression, and placed in long-term culture. Long-term  cultures were harvested 
at week 5 or 8, plated in methylcellulose,  and scored for colonies on day 14. LTC-IC were assumed to produce an average of four CFU after 5-8 
wk in culture (18). Enrichments  were calculated  by dividing  the frequency  of CFU in sorted fractions  by the frequency  for unsorted PI - cells. Recov- 
eries were calculated by multiplying  the enrichment by the percent sorted. 
and FL calls (not shown) but the majority of CD34 + cells 
from each source were c-kit + (Fig.  6, A, D, and G). In all 
instances  when CD34 was plotted against c-kit,  the c-kit  1~ 
cells expressed the highest levels of CD34 (data not shown) 
and Thy-1 expression was found to be restricted to cells that 
express intermediate to low levels of c-kit (Fig. 6, A, D, and 
G). Thy-1 expression was slightly lower on CB CD34 + cells 
than on comparable BM or FL ceils. 5E10-FITC was used 
in these experiments because detection of c-kit expression re- 
quired sensitive indirect staining. Staining with 5E10-FITC 
resulted in significantly weaker staining than in comparable 
stainings in which a biotinylated primary or secondary Ab 
was used (Fig. 2). The majority of Thy-1 +CD34 + cells were 
CD711~ in all tissues  and Thy-1 expression  decreased with 
increased CD71 expression (Fig. 6, B, E, and/-/). Similarly, 
Thy-1 staining was highest on CD38-CD34 + cells, and de- 
creased with increased  CD38 expression  (Fig.  6, C, F  and 
/).  Rh123  staining and Thy-1 expression  on BM CD34 + 
cells were inversely correlated (Fig. 7). Thy- 1 +  CD34 + cells 
were Rh123  auu, with Rh123  staining increasing as Thy-1 
expression  decreased.  Resolution  between  Rh123 aull and 
Rh123bng  ht cells was improved by incubating R_h123-stained 
samples  in medium at 37~  to allow dye efflux (compare 
Fig. 7, C and D). These FACS  |  data derived from three-color 
stainings indicate that Thy-1 has very restricted expression 
that, within the CD34 compartment, is confined to cells that 
are phenotypically similar to the most primitive hematopoi- 
etic cells. 
Phenotypic  Analysis  of Thy-12+CD34 -  Cells  in  BM and 
P/t  BM and PB cells were analyzed for the coexpression 
of Thy-1  and  various  lymphocyte and  myeloid markers. 
Samples were labeled with 5E10, 8G12 (anti-CD34), and var- 
ious lineage markers (Fig. 8), and Thy-12+CD34 -  cells (gate 
shown in Fig. 2 A) were analyzed for the expression  of lin- 
eage markers.  The Thy-1 gate was set high to include only 
cells that were more brightly stained than control-stained 
samples  (Fig.  2, A  and B).  It is possible  that, as a result, 
some weakly stained Thy-1 + cells were excluded, however, 
discrimination between specific and nonspecific  staining is 
difficult  in  this  region.  Thy-12+CD34 -  cells  comprised 
0.1-0.3% of low density BM and PB cells, including a small 
subset of lymphoid cells as judged by their light scatter. As 
shown in Fig. 8, the majority of Thy-12+CD34 -  cells were 
CD3 § and CD4 + , while a small proportion were CD8 + or 
CD9  weak. Cells observed  in cytospin preparations of Thy- 
12 +  CD34-  cells were small dense lymphocytes (results  not 
shown). 
Effect of mAb 5EI0 on Cells in Culture.  In an attempt to 
determine whether 5E10 had any functional effects on hema- 
topoietic cells in vitro, 5E10 or control Ab were added at 
10 #g/ml to purified BM cells (CD34+CD711~  l~ 
plated in Dexter type long-term cultures (2,000  cells/dish) 
and progenitor assays (400 cells/dish).  No significant differ- 
ence in colony formation was seen between the cultures with 
(22  colonies/dish)  or  without  added  5E10 Ab  (25  colo- 
nies/dish). Long-term cultures harvested after 5 wk produced 
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Figure  5.  5E10 staining of CD34 +  subpopulations in BM,  CB,  and FL.  Low density mononudear cells from FL,  CB,  and BM were stained in 
parallel with 5E10, anti-CD34,  and anti-CD45R.A.  Gates were set to exclude dead and high side scatter cells as shown in Fig.  1 to reduce nonspecific 
events, and to restrict analysis to CD34 + cells.  5E10 staining was strongest on CD34*CD45RA -  cells  previously shown to be highly enriched for 
LTC-IC.  Note  that 5E10 staining is stronger on FL  than CB or BM cells. 
172 and 141 colonies/dish for cultures with and without added 
5E10, respectively. Week 8 long-term cultures contained 70 
LTC-IC/dish for cultures with and without added 5E10. From 
these experiments it was concluded that, under conditions 
used, 5E10 did not appear to interfere with the production 
and/or formation of hematopoietic colonies from primitive 
hematopoietic cells. 
Discussion 
In this report we describe the distribution of Thy-1 on 
human hematopoietic cells. This work was performed with 
a new mAb, 5E10, which immunoprecipitated a 25-35-kD 
protein as reported for other anti-Thy-1 antibodies (24, 25), 
and was formally demonstrated to be directed against Thy-1 
by cDNA cloning. 
Thy-1 +  CD34 + cells were characterized as being function- 
ally and phenotypically the most primitive cells. This popu- 
lation was highly enriched for LTC-IC measured at weeks 
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5 and 8 and for HPP-CFC, and depleted of clonogenic cells. 
FACS  |  analysis indicated that Thy-1 expression was highest 
on CD34 + cells that were previously described  as being 
highly enriched for primitive hematopoietic cells (Figs. 5 and 
6), in that Thy-1 expression decreased with increased expres- 
sion of CD45RA,  CD38,  or CD71 expression (6, 7,  10). 
Our findings are in agreement with murine studies indicating 
that, among progenitor cells, Thy-1 expression decreases  with 
commitment and differentiation (26). Thy-1 expression ap- 
pears to be very low on CD34 + cells, as staining, even  with 
very sensitive techniques, was weak.  This weak staining is 
unlikely to reflect low Ab affinity because 5E10 could be used 
at relatively low concentrations  (<5 #g/ml), and certain cell 
lines, in addition to the rare population of CD34-Thy-12+ 
normal lymphoid cells, were very brightly stained even by 
directly conjugated Ab. 
CB, BM, and FL profiles obtained with 5E10 and CD34 
were quite similar except that CD34 and Thy-1 expression 
appeared higher on some FL cells than on any BM or CB FETAL 
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Figure  6.  Three-color  immuno- 
fluorescence staining of CD34  + 
cells in the light scatter gates (Fig. 
1) from BM, CB, and FL with 5E10 
and mAbs against the indicated cell 
surface molecules. 
cells, and CD34 + cells in most FL samples examined lacked 
CD45RA or expressed very little (Fig. 5, D, H, and L, respec- 
tively).  It is tempting  to speculate that  this population  of 
Thy-1>CD34 + cells represents a more primitive population 
of cells that is lost during ontogeny. Although background 
staining  was greater  on FL CD34 + cells  than  CB or BM 
CD34 + cells,  the increased 5E10 staining is unlikely to be 
a staining  artifact.  The higher background may be due to 
low affinity Fc3'R present  on  FL blast  cells  (27).  Indeed, 
when  FL  cells  were  stained  for  FoR  (CD16,  CD32)  a 
significant  proportion  (>30%)  of FL but <5%  of CB or 
BM CD34 + cells were found to express CD32 and CD16, 
in  agreement  with  findings  by  others  (27);  however,  all 
5E10+CD34 +  cells  were FoiL-  (results  not  shown).  The 
lack of CD45RA expression on the majority of FL CD34 + 
cells examined coincides with expression of CD45RO (W. 
Craig and P. M. Lansdorp, manuscript  in preparation)  and 
underscores the importance of CD45 isoform expression in 
the differentiation  of hematopoietic  cells  (7). 
Mast  cell growth  factor  (MGF),  a ligand  for  the  c-kit 
receptor tyrosine kinase, has powerful synergistic effects with 
other early-acting growth factors on primitive hematopoi- 
etic cells (6, 16), and murine studies indicate that the most 
primitive hematopoietic cells (those with marrow repopulating 
ability) are c-kit + (28). We found low levels of c-kit  expres- 
sion on human hematopoietic cells that express Thy-1. Be- 
cause Thy-1 expression appears restricted to phenotypically 
and functionally the most primitive cells (this report), it thus 
appears that such cells express low levels of c-kit.  All CD34 + 
Rh123 aull cells were Thy-1 + , with Thy-1 expression being 
inversely related to Kh123 staining (Fig.  7).  This is in con- 
trast to the findings ofBaum et al. (4), who found that Thy- 
1 +  CD34 + cells could be subdivided using 1Lh123 staining, 
however, no data were shown. 
The function of BM and CB Thy-12+CD34 -  lymphoid 
cells is unknown.  The CD3 +CD4 + phenotype suggests a 
mature cell type, and FACS|  CD34-5E10 + cells in- 
deed appeared to be small lymphocytes in cytospin prepara- 
tions. The proportion of Thy-1 + lymphocytes increased dra- 
matically  upon  stimulation  of PBL with  PHA  and  IL-2, 
suggesting that Thy-1 expression is perhaps related to T cell 
activation (results not shown). To our knowledge, this is the 
first report of Thy-1 + lymphocytes in normal human BM, 
although previous reports describe a population of Thy-1 + 
thymocytes believed to  be prothymocytes  (25).  The  only 
other report of mature Thy-1 + cells described a population 
of Thy-l+-infiltrating  leukocytes in  several  patients  with 
malignant breast tumors, however, this population was not 
further  characterized  (29). 
The function of Thy-1 on hematopoietic stem cells is un- 
1338  Thy-1  Expression on Human Hematopoietic Progenitor Cells Table  3.  The Percentage  of Thy-1 + Cells among  Cells within  the Indicated  Gate/Phenotype 
CD34 + cells 
Sample  PI gate  LS gate  All  CD71-  CD38-  CD45RA-  c-kit + 
NBM  2.4  -  25(2.7)  45  80  -  - 
4.2  4.0  20(3.2)  15  32  25  - 
2.5  5,2  41(2.3)  75  75  52  70 
2.5  2.0  26(1.7)  .... 
1.0  1.0  22(3.2)  .... 
2.0  4.5  27(4.0)  -  87  -  - 
1.8  2.4  21(1.5)  .... 
0  0  12(2.5)  .... 
2.6  0.6  30(4.6)  -  -  40  50 
PB  0.2 
0.3 
0.7 
CB  5.8  1.2  54(0.4)  56  45  -  - 
o  o  lO(1.o)  -  -  20  - 
1.6  0  25(0.4)  -  -  30  - 
4.5  3.5  40(1.4)  -  -  43  40 
FL  3.0  3.0  18(1.0)  30  25  20  70 
7.0  7.0  35(7.4)  50  65  45  60 
1.4  1.3  38(1.3)  65  80  50  30 
The reactivity of 5E10 with phenotypically  defined mononuclear cells from normal bone marrow (NBM), PB,  CB, and FL. Results are expressed 
as the percent positive cells among the indicated  cell fraction  (-, not tested).  The percent  of Thy-1 + cells was determined by subtracting  percent 
positive for the isotype control from the percent  of 5E10 § cells. Gates were set as in Fig. 1. The percent  of CD34+cells in the PI and light scatter 
gates  of a sample is shown in parentheses. 
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CD34 + adult BM cells. Cells were labeled with 8G12-CyS, Rb123,  and 
either an irrelevant  isotype-matched  control Ab (A and B) or 5E10 (C 
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known. Rat stem cells express more Thy-1 than primitive 
hematopoietic cells of murine (30) or human origin, but the 
fact that Thy-1 expression is conserved on these cells implies 
an important role for Thy-1 in early hematopoiesis. Recently 
it was reported that some cells with marrow repopulating 
ability  (presumably  stem  cells) were Thy-1-  in  Thy-l.2 
strains of mice, whereas all cells with marrow-repopulating 
ability  in Thy-l.1  strains were Thy-1 + (31). However,  in 
view of the weak expression of Thy-1 on hematopoietic cells, 
these findings may reflect unusual binding properties of the 
Abs used. 
Thy-1 has been postulated to be involved in cellular recog- 
nition (32, 33),  adherence (34, 35),  and T  cell activation 
(36-39). Some Abs against Thy-1 are able to stimulate intra- 
cellular  Ca  2+  release (36) and  phosphorylation  of cyto- 
plasmic proteins (40), suggesting Thy-1 may be involved in 
cell activation. Thy-1 is anchored in the membrane by a phos- 
and D). After Rh123  staining at 37~  samples were split and either left 
on ice at 4~  (A and C) or incubated  an additional  20 rain at 37~  (B 
and D) to allow dye efflux. Within the CD34 gate, Thy-1 expression (5E10 
staining)  and Rh123  staining  appeared to be reversibly correlated. mlgG 1 
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Figure  8.  Lineage marker expression on 5E10Z+CD34 - 
cells. Normal BM cells were labeled with an anti-CD34 
Ab, 5E10,  and various lineage markers.  Histograms  on 
the left are the fluorescence profiles (log scale) for all viable 
low density mononuclear cells obtained with the indicated 
marker,  whereas histograms  on the right represent  lin- 
eage marker  expression  on  cells  in  the  5E102+CD34 - 
gate shown in Fig.  2 A. 
phatidylinositol anchor and has no direct link to the cytoplasm 
(41);  therefore, if it has a role in transmembrane signaling, 
additional associated proteins would be required. Some rou- 
tine studies have linked Thy-1 to CD45  (a transmembrane 
protein with tyrosine phosphatase activity) in cocapping, and 
crosslinking and immunoprecipitation studies (42, 43). Anti- 
Thy-1  Abs  also  coimmunoprecipitate  p56  lck  (44),  (a  src- 
related tyrosine kinase that can associate with CD45) from 
murine T cells (45). It is tempting to speculate that on human 
hematopoietic cells, Thy-1 and CD45KO could be function- 
ally associated, given their coexpression on the most primi- 
tive  CD34 +  cells,  and  the  biochemical  data  physically 
linking CD45  and Thy-1 in the murine system (42-45). 
Thy-1 may be important in stromal adherence, possibly 
providing a growth inhibitory signal as has been suggested 
for neuronal Thy-1 (46). Studies on myogenesis (47) and mu- 
fine thymocytes (35) have indicated that Thy-1 may function 
as a receptor for a ligand on other cells allowing cells to con- 
tact and adhere. Thy-1 may have an analogous role on stem 
cells, allowing them to recognize and bind to stromal deter- 
minants.  The  lower  expression  of  Thy-1  on  circulating 
CD34 § cells from umbilical CB may result from a reduced 
requirement for adherence and is in agreement with this pro- 
posed function of Thy-1. 
mAbs against human Thy-1 appear to be attractive tools 
for stem cell purification techniques because of the very re- 
1340  Thy-1  Expression on Human  Hematopoietic Progenitor  Cells stricted pattern of Thy-1 expression within the human he- 
matopoietic system and the possibility to target such rare cells 
by immunoaffmity techniques. Anti-Thy-1 Abs have been 
used previously for the purification of murine (48,  49),  rat 
(50), and recently human fetal BM stem cells (4). Our findings 
indicate that anti-Thy-1 Abs appear useful for the purification 
of adult stem cells from human BM as well. Compared with 
the studies reported by Baum et al. (4), we found a higher 
percentage of Thy-1 +  CD34 + cells, but this probably reflects 
differences in the Abs used. In previous studies anti-Thy-1 
Abs have been used to purge marrow for autologous BM trans- 
plantation in neuroblastoma patients because  the majority 
of malignant neuronal tumors express very high levels of  Thy-1 
(24, 51). While such techniques  may spare Thy-1 + BM cells 
because of their much lower Thy-1 expression, improvements 
in purging techniques could result in the unwanted elimina- 
tion of Thy-1 +  hematopoietic cells,  and  such techniques 
should therefore be approached with caution. 
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